ELDN logo

Eledon Pharmaceuticals, Inc.

ELDN
Healthcare|Biotechnology|US
$2.60
+0.14 (+5.89%)
DCF Value
$0.24
Tangible Book / Share
$0.35
Cash / Share
$0.78
Next Earnings Report
Nov 13, 2026
EPS est. -$0.20
Financing Filings (last 12 months)
3
Shelf registrations / offering prospectuses — latest May 1, 2026 (S-3). Possible dilution.

Upcoming Data Readouts (3)

Jan 2027
Est. completion
P1P2Prevention of Rejection in Kidney Transplant
Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant
NCT05027906n=48
Mar 2029
Est. completion
P1P2Type 1 Diabetes Mellitus
Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)
NCT06305286n=70
Dec 2030
Est. completion
Early P1Kidney Failure
Tolerance Through Mixed Chimerism (Sip-Tego)
NCT06972069n=12

Recent Press Releases

Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual Meeting
Oct 26, 2026 · GlobeNewsWire
Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting
Oct 5, 2026 · GlobeNewsWire
Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society
Sep 22, 2026 · GlobeNewsWire
Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society
Sep 9, 2026 · GlobeNewsWire
Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026
Sep 3, 2026 · GlobeNewsWire
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Aug 13, 2026 · GlobeNewsWire

SEC Filings (54)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 30, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Sep 4, 2026S-8Employee stock planDocumentIndex
Aug 13, 202610-QQuarterly reportDocumentIndex
Aug 13, 20268-KMaterial eventDocumentIndex
Jul 31, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jun 22, 20268-KMaterial eventDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 13, 202610-QQuarterly reportDocumentIndex
May 13, 20268-KMaterial eventDocumentIndex
May 11, 2026EFFECTDocumentIndex
May 1, 2026S-3Shelf registrationDocumentIndex
Apr 30, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 30, 2026ARSAnnual report to holdersDocumentIndex
Apr 30, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 27, 2026SC 13GPassive 5%+ stakeDocumentIndex
Apr 21, 2026PRE 14AProxy / shareholder voteDocumentIndex
Mar 26, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Mar 19, 202610-KAnnual reportDocumentIndex
Mar 19, 20268-KMaterial eventDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 13, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jan 21, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jan 2, 20268-KMaterial eventDocumentIndex
Nov 24, 2025SC 13GPassive 5%+ stakeDocumentIndex
Nov 14, 20258-KMaterial eventDocumentIndex
Nov 14, 202510-QQuarterly reportDocumentIndex
Nov 13, 20258-KMaterial eventDocumentIndex
Nov 13, 2025424B5Offering prospectusDocumentIndex
Nov 12, 2025424B5Offering prospectusDocumentIndex
Nov 7, 20258-KMaterial eventDocumentIndex
Aug 14, 202510-QQuarterly reportDocumentIndex
Aug 14, 202510-Q/AQuarterly reportDocumentIndex
Aug 14, 202510-K/AAnnual reportDocumentIndex
Aug 14, 20258-KMaterial eventDocumentIndex
Aug 6, 20258-KMaterial eventDocumentIndex
Jul 29, 2025SC 13GPassive 5%+ stakeDocumentIndex
Jul 17, 2025SC 13GPassive 5%+ stakeDocumentIndex
Jun 12, 20258-KMaterial eventDocumentIndex
May 14, 202510-QQuarterly reportDocumentIndex
May 14, 20258-KMaterial eventDocumentIndex